A Combination of Ursolic Acid and Oleanolic Acid Disrupts Bioenergetic Homeostasis in Prostate Cancer and Inhibits Cancer Growth by Cytotoxic Autophagy
Open Access
- 22 September 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8448
Abstract
Oleanolic acid (OA) and ursolic acid (UA) are bioactive pentacyclic triterpenoids (PTTs) and potential therapeutics for cancers. If tested individually, their therapeutic efficacy is limited. The antitumor potential of OA, UA, and their combination was tested against castration-resistant prostate cancer cells (CRPCs) in vitro and in vivo. UA, OA, and UA + OA (1:1) inhibited the cell proliferation and clonogenic growth of CRPC cells. Compared to the potency of individual OA and UA on these cells, their potency was synergistically enhanced when tested as an OA + UA mix. Neither of these compounds inhibited the proliferation of normal prostate epithelial cells. Further, in a CRPC (22Rv1) tumor model, the gavage of UA and, more effectively, the OA + UA mix inhibited tumor growth ≥ 60%, without measurable systemic toxicity. Mechanistic studies showed that these PTTs increase cyto-plasmic and mitochondrial oxidative stress. Cytotoxicity was predominantly triggered by high levels of reactive oxygen species (ROS). It was abolished when cells were co-treated with N-acetylcysteine (NAC), an oxygen scavenger and precursor for glutathione synthesis. The PTTs caused cell cycle arrest at the G1/S boundary, reduced glucose utilization, reprogrammed mitochondrial bioenergetics, and cytotoxic autophagy. Further, these data showed that cytotoxic autophagy is a significant contributor to PTT-induced tumor inhibition and OA + UA, at a 1:1 mix, selectively targets bioenergetics in prostate cancer cells, leading to ROS-mediated cytotoxic autophagy and robust tumor inhibition without significant systemic toxicity.Keywords
Funding Information
- U.S. Department of War (HT9425-23-1-0761)
- National Institute of Health (NIDDK R01DK140376-02)
- Dr. J. Harold Harrison Endowment Chair, Augusta University
This publication has 59 references indexed in Scilit:
- Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approachesCancer, 2025
- Evaluation of Oxygen Consumption Rates In Situ2024
- A Plate Reader-Based Measurement of the Cellular ROS Production Using Dihydroethidium and MitoSOX2022
- Gliadin induced oxidative stress and altered cellular responses in human intestinal cells: An in‐vitro study to understand the cross‐talk between the transcription factor Nrf‐2 and multifunctional APE1 enzymeJournal of Biochemical and Molecular Toxicology, 2022
- Mitigation of Gliadin-Induced Inflammation and Cellular Damage by Curcumin in Human Intestinal Cell LinesInflammation, 2021
- Histone Methyltransferase Setd7 Regulates Nrf2 Signaling Pathway by Phenethyl Isothiocyanate and Ursolic Acid in Human Prostate Cancer CellsMolecular Nutrition & Food Research, 2018
- Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cellsApoptosis, 2017
- Ursolic acid promotes cancer cell death by inducing Atg5‐dependent autophagyInternational Journal of Cancer, 2013
- Functional Remodeling of Benign Human Prostatic Tissues In Vivo by Spontaneously Immortalized Progenitor and Intermediate CellsStem Cells, 2009
- Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non‐antimicrobial tetracycline analog (COL‐3) in a metastatic prostate cancer modelInternational Journal of Cancer, 2001